Validity of a PCR assay in CSF for the diagnosis of neurocysticercosis
Authors:
- Arturo CarpioACArturo Carpio
- Alfredo CampoverdeACAlfredo Campoverde
- Matthew L. RomoMRMatthew L. Romo
- Lorena GarcíaLGLorena García
- Luis M. PiedraLPLuis M. Piedra
- Mónica PacurucuMPMónica Pacurucu
- Nelson LópezNLNelson López
- Jenner AguilarJAJenner Aguilar
- Sebastian LópezSLSebastian López
- Luis C. VintimillaLVLuis C. Vintimilla
- Ana M. ToralATAna M. Toral
- Pablo Peña-TapiaPPPablo Peña-Tapia
Open Access
- 1 March 2017
- journal article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 4 (2) , e324
Abstract
Objective: To prospectively evaluate the validity of a PCR assay in CSF for the diagnosis of neurocysticercosis (NC). Methods: We conducted a multicenter, prospective case-control study, recruiting participants from 5 hospitals in Cuenca, Ecuador, from January 2015 to February 2016. Cases fulfilled validated diagnostic criteria for NC. For each case, a neurosurgical patient who did not fulfill the diagnostic criteria for NC was selected as a control. CT and MRI, as well as a CSF sample, were collected from both cases and controls. The diagnostic criteria to identify cases were used as a reference standard. Results: Overall, 36 case and 36 control participants were enrolled. PCR had a sensitivity of 72.2% (95% confidence interval [CI] 54.8%–85.8%) and a specificity of 100.0% (95% CI 90.3%–100.0%). For parenchymal NC, PCR had a sensitivity of 42.9% (95% CI 17.7%–71.1%), and for extraparenchymal NC, PCR had a sensitivity of 90.9% (95% CI 70.8%–98.9%). Conclusions: This study demonstrated the usefulness of this PCR assay in CSF for the diagnosis of NC. PCR may be particularly helpful for diagnosing extraparenchymal NC when neuroimaging techniques have failed. Classification of evidence: This study provides Class III evidence that CSF PCR can accurately identify patients with extraparenchymal NC.Keywords
This publication has 10 references indexed in Scilit:
- New diagnostic criteria for neurocysticercosis: Reliability and validityAnnals of Neurology, 2016
- Parasitic diseases of the central nervous system: lessons for clinicians and policy makersExpert Review of Neurotherapeutics, 2016
- Relevance of 3D magnetic resonance imaging sequences in diagnosing basal subarachnoid neurocysticercosisActa Tropica, 2015
- High Prevalence of Cysticercosis in People with Epilepsy in Southern RwandaPLOS Neglected Tropical Diseases, 2013
- Imaging of NeurocysticercosisNeuroimaging Clinics Of North America, 2012
- Confirmation and Follow-Up of Neurocysticercosis by Real-Time PCR in Cerebrospinal Fluid Samples of Patients Living in FranceJournal of Clinical Microbiology, 2011
- Human Neurocysticercosis: Comparison of Different Diagnostic Tests Using Cerebrospinal FluidJournal of Clinical Microbiology, 2011
- Neurocysticercosis: detection ofTaenia soliumDNA in human cerebrospinal fluid using a semi-nested PCR based on HDP2Pathogens and Global Health, 2008
- Taenia solium DNA is present in the cerebrospinal fluid of neurocysticercosis patients and can be used for diagnosisEuropean Archives of Psychiatry and Clinical Neuroscience, 2006
- Diagnosis of Atypical Neurocysticercosis by Polymerase Chain Reaction Analysis: Case ReportClinical Infectious Diseases, 1999